Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
Completed
Conditions studied: Heart Failure
In brief
This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A \& B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest potential for performance improvement (with respect to improving quality and efficiency of care for HF patients) through optimized utilization of sacubitril/valsartan.
Key facts
- Study ID
- NCT05096039
- Run by
- Novartis Pharmaceuticals
- People needed
- 1614719
- Starts
- 2020-04-10
- Expected to finish
- 2020-09-30
- Last updated by the study team
- 2021-12-16
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ≥18 years old during year of index date with valid gender and geographic information
- Continuous enrollment (CE) in the health plan with medical and pharmacy benefits for ≥6 months (180ii days) before the index date (pre-index period)
- CE with medical and pharmacy benefits for ≥18 months (540ii days) beginning on the index date (post-index period)
- All patients had uniform 6-month pre-index and 18-month post-index periods
- ≥1 medical claim with an MS diagnosis codeiii in any position during the pre-or post-index periods
- ≥1 claim for fingolimod after the index date (i.e., from index date +1 to 539 days post-index)
- By requiring ≥1 medical claim with an MS diagnosis code and ≥2 claims with an NDC for fingolimod, the inclusion criteria essentially incorporated the preferred/overall best performing MS case-finding definition validated by Culpepper et al. The criteria for that definition required at least 3 separate encounters from any of the following: MS-related ambulatory visits, MS-related inpatient stays, and DMT claims during a 12-month period. Slightly higher accuracy was found when a 24-month period was used.
You may not qualify if…
- ≥1 pharmacy or medical claim for any MS DMT during the pre-index period
Where it is running
- Novartis Pharmaceuticals — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.